Emerging Technologies for Diabetes Care

Bailey, Timothy S.; Walsh, John; Stone, Jenine Y

doi:10.1089/dia.2018.0115

Cited by 35 publications

(49 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, only a small proportion of participants entered their insulin doses as compared with BGL. Automation, such as the use of cloud-connected insulin pen devices, is likely to improve clinician access to data 14. Although the participants continued to have a few Bluetooth connectivity issues between the app and the glucose-meter, the majority of participants agreed that there were no technical problems using the system; this was an improvement on the proof-of-concept trial.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of a feasibility trial using an innovative mobile health programme to assist in insulin dose adjustment

Menon

Fatehi

Ding

et al. 2019

BMJ Health Care Inform

View full text Add to dashboard Cite

ObjectiveIntensification of diabetes therapy with insulin is often delayed for people with suboptimal glycaemic control. This paper reports on the feasibility of using an innovative mobile health (mHealth) programme to assist a diabetes insulin dose adjustment (IDA) service.MethodsTwenty adults with diabetes referred to a tertiary hospital IDA service were recruited. They were provided with a cloud-based mobile remote monitoring system—the mobile diabetes management system (MDMS). The credentialled diabetes educator (CDE) recorded the time taken to perform IDA utilising the MDMS versus the conventional method—which is a weekly adjustment of insulin doses by a CDE through telephone contact based on three or more daily blood glucose readings. Participants and staff completed a feedback questionnaire.ResultsThe CDE spent 55% less time performing IDA using MDMS than using the conventional method. The participants were satisfied with MDMS use and the CDEs reported improved efficiency.ConclusionIncorporating a mHealth programme for an IDA service has the potential to improve service delivery efficiencies while simultaneously improving the patient experience.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of a feasibility trial using an innovative mobile health programme to assist in insulin dose adjustment

Menon

Fatehi

Ding

et al. 2019

BMJ Health Care Inform

View full text Add to dashboard Cite

show abstract

“…Certainly, enhancement in treatment satisfaction may play a critical role in increasing patient self-efficacy and commitment to therapy, thereby supporting in reaching long-term stable glycemic control, in addition to the minimization of the risk of diabetic complications [18]. More recently, diabetes technology has extended, and studies reported that technological improvements in glucometers are enhanced diabetes management and patient satisfaction [19,[23][24][25]. In this present study, we explored whether the smartLIGHT™ based BGM can impact the clinical characteristics and GMS in T2D patients over a period of time.…”

Section: Discussionmentioning

confidence: 99%

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Hayek¹,

Robert²,

Dawish³

2020

Cureus

View full text Add to dashboard Cite

Introduction Self-monitoring of blood glucose (SMBG) plays an important role in diabetes management. The Contour ® Next One glucometer is a recent glucometer that delivers blood glucose results by an immediate color indicator to aware users when blood glucose is at a critical high or low. The main purpose of the study was to assess the impact of an application of a blood glucose meter (BGM) having a color range indicator on clinical characteristics and glucose monitoring satisfaction (GMS) among patients having type 2 diabetes (T2D). Methods A total of 85 (male 42 and female 43) patients with T2D were switched to a BGM having smartLIGHT™ target range indicator (blood glucose meters featuring color range indicator) using Contour ® Next One glucometer. Demographic data, as well as glycemic control, were collected at baseline and 12 weeks. At the time of the baseline and 12 weeks of the study, a trained interviewer gave the GMS survey questionnaire to every patient in order to collect the glucose monitoring satisfaction. In addition to GMS, a patient's perceptions of smartLIGHT™ feature satisfaction survey responses were also collected from the patients at the end of the study (12 weeks). Results Compared to baseline, a significant improvement was observed in the subdomains of glucose monitoring satisfaction survey (GMSS) score on openness (p=0.0001), emotional burden (p=0.0001), behavioral burden (p=0.0001), and trust (p=0.0001) at the end of the study. Overall, the total GMS score at baseline was 2.61 ± 0.51, which improved up to 3.16 ± 0.63 (p=0.0001) during the period of 12 weeks. The patient satisfaction with smartLIGHT™ survey outcomes exposed evidence of satisfaction among the study population at the end of the study. There were statistically insignificant reductions observed in glycosylated hemoglobin (HbA1c) (p=0.063) and the frequency of hypoglycemia (p=0.057) at the end of the study. Conclusions The study demonstrates a significant improvement in the subdomains of GMSS-openness, emotional burden, behavioral burden, and trust-at 12 weeks than at the baseline, with the increased total GMSS score. Similarly, high satisfaction with the color-based smartLIGHT™ feature was also observed at the end of the study.

show abstract

“…Bigfoot Biomedical is developing an insulin smart pen that will connect to the FreeStyle Libre system. It will be controlled with a mobile app and hopefully adjust long and short acting insulin doses without manual input [53].…”

Section: Smart Pen Systemsmentioning

confidence: 99%

“…Additionally, smartphone technology has decreased the cost and complexity of data sharing. The use of automated uploads from devices to the "cloud" has allowed both patient and physician to have almost real-time access to data [53].…”

Section: Mobile and Computer Applications (Apps)mentioning

confidence: 99%

Newer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology

Schorr¹

2019

Type 2 Diabetes [Working Title]

View full text Add to dashboard Cite

This chapter will focus on the technological advances for individuals with Type 2 diabetes mellitus and their effect on treatment, control of blood glucoses and possible improvement in lifestyle and decreasing complications. This is a general overview of technological improvements and not an outline for specific patient care. Various technologies will be discussed and the outlook for future improvements outlined.

show abstract

Emerging Technologies for Diabetes Care

Cited by 35 publications

References 47 publications

Outcomes of a feasibility trial using an innovative mobile health programme to assist in insulin dose adjustment

Outcomes of a feasibility trial using an innovative mobile health programme to assist in insulin dose adjustment

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Newer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology

Contact Info

Product

Resources

About